Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00038519 | Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor | PHASE2 | COMPLETED | 16 | — | — | Apr 1, 2001 | - | Jul 28, 2006 | 52 | United States, Argentina +8 |
| NCT00038532 | Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART | PHASE2 | COMPLETED | 24 | — | — | Apr 1, 2001 | - | Apr 1, 2008 | 54 | United States, Argentina +9 |
| Name | Type | Description |
|---|---|---|
| Amprenavir/ritonavir | DRUG | - |
| Saquinavir/ritonavir | DRUG | - |
| Efavirenz | DRUG | - |
Inclusion: * Subject must remain on current antiretroviral therapy during screening until a new regimen is initiated. * Subject demonstrates reduced susceptibility to lopinavir. * Subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still ...